Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Impact · against what's priced in

The vaccine sector is experiencing concentrated capital flight, with Novavax and Moderna suffering significant declines. While Moderna's drop aligns with general sector volatility, Novavax faces additional pressure from a reaffirmed Sell rating and its total reliance on Sanofi for commercial success.

MRNA−0.40

Challenges what's priced in

The price assumes

The current respiratory vaccine franchise, which generated $1.94 billion in FY2025 revenue